Claims
- 1. N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]acetamide or a pharmaceutically acceptable salt thereof.
- 2. (E)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-ylidene)ethylamine or a pharmaceutically acceptable salt thereof.
- 3. 2-(1,6,7,8-Tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethylamine or a pharmaceutically acceptable salt thereof.
- 4. A pharmaceutical composition which comprises a compound or salt as claimed in any one of claims 1-3 and a pharmaceutically acceptable carrier.
- 5. A composition as claimed in claim 4 wherein said compound or said salt has a binding affinity for melatonin receptor.
- 6. Method for treating or preventing disorders related to the action of melatonin in mammals which comprises administrating to a subject in need thereof a therapeutically effective amount of a composition as claimed in claim 5.
- 7. A method as claimed in claim 6 which regulates circadian rhythm.
- 8. A method as claimed in claim 6 which regulates sleep-awake rhythm.
- 9. A method as claimed in claim 6 which regulates time zone change syndrome.
- 10. A method as claimed in claim 6 which treats or prevents sleep disorders.
Priority Claims (3)
Number |
Date |
Country |
Kind |
8-051491 |
Mar 1996 |
JP |
|
8-183667 |
Jul 1996 |
JP |
|
9-029185 |
Feb 1997 |
JP |
|
Parent Case Info
This application is a division of Ser. No. 08/812,168 filed Mar. 6, 1997.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
5296482 |
Peglion et al. |
Mar 1994 |
|
5552418 |
Depreux et al. |
Sep 1996 |
|
5661186 |
Takaki et al. |
Aug 1997 |
|